Dynamics of RAS Mutations in Liquid Biopsies in Metastatic Colorectal Cancer Patients—Case Series and Literature Review
Open accessThe DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Abstract
Liquid biopsies can accurately identify molecular alterations in patients with colorectal cancer with high concordance with tissue analysis and shorter turnaround times. Circulating tumor (ct) DNA analysis can be used for diagnosing and monitoring tumor evolution in patients with metastatic colorectal cancer who are treated with EGFR inhibitors. In this article, we reported three clinical cases to illustrate the relevance of RAS mutations identified in ctDNA samples of patients with wild-type metastatic colorectal cancer who received an EGFR inhibitor plus chemotherapy as first-line treatment. The identification of RAS mutations in these patients is one of the most frequently identified mechanisms of acquired resistance. However, detecting a KRAS mutation via liquid biopsy can be caused by inter-tumor heterogeneity or it can be a false positive due to clonal hematopoiesis. More research is needed to determine whether ctDNA monitoring may help guide therapy options in metastatic colorectal cancer patients. We performed a literature review to assess the technologies that are used for analysis of RAS mutations on ctDNA, the degree of agreement between tissue and plasma and the importance of tissue/plasma discordant cases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Low-frequency subclonal RAS mutations, which can be missed by conventional sequencing, can also lead to intrinsic resistance, necessitating the need for highly sensitive methods like next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) analysis to detect mutations and guide treatment strategies [14].”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774 · cited 1×
“Furthermore, liquid biopsy is able to capture the tumor heterogeneity that appears during treatment before radiological progression [8].”
BackgroundDetection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Integrating liquid biopsies into the management of cancer
Siravegna, G., Marsoni, S., Siena, S., & Bardelli, A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.14 · Cited by 1,908 · cited 3×
“Primary resistance refers to the presence of activating mutations in these genes prior to treatment initiation, while the selection of pre-existing mutant clones or de novo acquisition of mutations under the influence of anti-EGFR treatment is known as acquired resistance [6].”
BackgroundEmergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889 · cited 2×
“In this patient population, RAS/BRAF-acquired mutations were detected at the time of disease progression [15–17].”
BackgroundCervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796 · cited 1×
“…likely to benefit from the administration of chemotherapy doublets, including FOLFOX (5-Fluouracil, folinic acid and oxaliplatin), CAPOX (capecitabine and oxaliplatin) and FOLFIRI (5-Fluouracil, folinic acid and irinotecan), in conjunction with EGFR-inhibitors such as Cetuximab or Panitumumab [2].”
BackgroundThe molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers
Diaz Jr, L. A., Williams, R. T., Wu, J., Kinde, I., Hecht, J. R., Berlin, J., Allen, B., Bozic, I., Reiter, J. G., Nowak, M. A., et al. (2012) · Nature · doi:10.1038/nature11219 · Cited by 1,713 · cited 1×
“Besides primary resistance mechanisms, the efficacy of anti-EGFR agents in mCRC is limited by the development of molecular alterations producing acquired resistance [7,16,48,49].”
BackgroundClonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Siravegna, G., Mussolin, B., Buscarino, M., Corti, G., Cassingena, A., Crisafulli, G., Ponzetti, A., Cremolini, C., Amatu, A., Lauricella, C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3870 · Cited by 1,082 · cited 2×
“This phenomenon has been confirmed in several reports, although the rate of patients who become RAS-mutant at progression significantly differs among the various studies [10,15,22,30,51–54].”
BackgroundResultIntegrating genomic features for non-invasive early lung cancer detection
Chabon, J. J., Hamilton, E. G., Kurtz, D. M., Esfahani, M. S., Moding, E. J., Stehr, H., Schroers-Martin, J., Nabet, B. Y., Chen, B., Chaudhuri, A. A., et al. (2020) · Nature · doi:10.1038/s41586-020-2140-0 · Cited by 685 · cited 1×
“Enhanced understanding of the molecular features of clonal hematopoiesis coupled with machine learning could represent the optimal solution for paired sequencing with white blood cells [61].”
BackgroundClinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA
Thierry, A. R., Mouliere, F., El Messaoudi, S., Mollevi, C., Lopez-Crapez, E., Rolet, F., Gillet, B., Gongora, C., Dechelotte, P., Robert, B., et al. (2014) · Nature Medicine · doi:10.1038/nm.3511 · Cited by 678 · cited 2×
“Numerous studies investigating inter-tumor heterogeneity (between primary tumors and metastases in the same patient) have demonstrated mutational discordance in up to 30% of cases [24,56,57].”
BackgroundMethodFalse-Positive Plasma Genotyping Due to Clonal Hematopoiesis
Hu, Y., Ulrich, B. C., Supplee, J., Kuang, Y., Lizotte, P. H., Feeney, N. B., Guibert, N. M., Awad, M. M., Wong, K.-K., Jänne, P. A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0143 · Cited by 457 · cited 2×
“Previous studies have shown that genes such as TP53 and KRAS can be mutated in white blood cells [58,59].”
BackgroundVidal, J., Muinelo, L., Dalmases, A., Jones, F., Edelstein, D., Iglesias, M., Orrillo, M., Abalo, A., Rodríguez, C., Brozos, E., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx125 · Cited by 344 · cited 3×
“There are data suggesting that resistant mutations detected at very low variant allele frequency (VAF) represent small subclones of the total tumor burden and do not predict lack of response to anti-EGFR treatment [15].”
BackgroundResultGenomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
Strickler, J. H., Loree, J. M., Ahronian, L. G., Parikh, A. R., Niedzwiecki, D., Pereira, A. A. L., McKinney, M., Korn, W. M., Atreya, C. E., Banks, K. C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1009 · Cited by 295 · cited 1×
“Studies have demonstrated that ctDNA analysis can accurately identify molecular alterations in patients with CRC with high concordance with tissue analysis and shorter turnaround times [9–14].”
BackgroundKnijn, N., Mekenkamp, L. J. M., Klomp, M., Vink-Börger, M. E., Tol, J., Teerenstra, S., Meijer, J. W. R., Tebar, M., Riemersma, S., van Krieken, J. H. J. M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.26 · Cited by 291
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer
Arena, S., Bellosillo, B., Siravegna, G., Martínez, A., Cañadas, I., Lazzari, L., Ferruz, N., Russo, M., Misale, S., González, I., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2821 · Cited by 271 · cited 1×
“Besides primary resistance mechanisms, the efficacy of anti-EGFR agents in mCRC is limited by the development of molecular alterations producing acquired resistance [7,16,48,49].”
BackgroundMorelli, M. P., Overman, M. J., Dasari, A., Kazmi, S. M. A., Mazard, T., Vilar, E., Morris, V. K., Lee, M. S., Herron, D., Eng, C., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv005 · Cited by 254
Analysis of Mutations in DNA Isolated From Plasma and Stool of Colorectal Cancer Patients
Diehl, F., Schmidt, K., Durkee, K. H., Moore, K. J., Goodman, S. N., Shuber, A. P., Kinzler, K. W., & Vogelstein, B. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.05.039 · Cited by 228 · cited 1×
“…patients diagnosed initially with wild-type mCRC. Circulating tumor DNA (ctDNA) levels are found to correlate with a number of biological and clinicopathological characteristics, including tumor burden, stage, histotype, apoptotic rate, proximity to blood vessels, and metastatic potential [19–21].”
BackgroundMerker, J. D., Oxnard, G. R., Compton, C., Diehn, M., Hurley, P., Lazar, A. J., Lindeman, N., Lockwood, C. M., Rai, A. J., Schilsky, R. L., et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0901-sa · Cited by 220 · cited 1×
“On the other hand, the limitations of liquid biopsy include mainly the reliance of results on tumor volume, and the lack of a standard technique for analysis [47].”
BackgroundAcquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
Van Emburgh, B. O., Arena, S., Siravegna, G., Lazzari, L., Crisafulli, G., Corti, G., Mussolin, B., Baldi, F., Buscarino, M., Bartolini, A., et al. (2016) · Nature Communications · doi:10.1038/ncomms13665 · Cited by 214 · cited 1×
“This phenomenon has been confirmed in several reports, although the rate of patients who become RAS-mutant at progression significantly differs among the various studies [10,15,22,30,51–54].”
ResultCurrent and Emerging Applications of Droplet Digital PCR in Oncology
Olmedillas-López, S., García-Arranz, M., & García-Olmo, D. (2017) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-017-0278-8 · Cited by 201 · cited 1×
“Droplet digital PCR (ddPCR) is a highly sensitive, specific and precise technique that facilitates the identification and quantification of specific DNA alterations in various clinical specimens [37].”
BackgroundGrasselli, J., Elez, E., Caratù, G., Matito, J., Santos, C., Macarulla, T., Vidal, J., Garcia, M., Viéitez, J. M., Paéz, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx112 · Cited by 187 · cited 2×
“Similar previous studies showed a concordance of 89.7–93.3%, which indicates that the detection of RAS mutations in the blood through liquid biopsy and BEAMing technology may be a useful replacement to tumor testing [26,28,44].”
ResultInfluentialClonal Hematopoiesis in Liquid Biopsy: From Biological Noise to Valuable Clinical Implications
Chan, H. T., Chin, Y. M., Nakamura, Y., & Low, S.-K. (2020) · Cancers · doi:10.3390/cancers12082277 · Cited by 183 · cited 2×
“Previous studies have shown that genes such as TP53 and KRAS can be mutated in white blood cells [58,59].”
BackgroundPietrantonio, F., Vernieri, C., Siravegna, G., Mennitto, A., Berenato, R., Perrone, F., Gloghini, A., Tamborini, E., Lonardi, S., Morano, F., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1863 · Cited by 182
Bachet, J. B., Bouché, O., Taieb, J., Dubreuil, O., Garcia, M. L., Meurisse, A., Normand, C., Gornet, J. M., Artru, P., Louafi, S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy061 · Cited by 178 · cited 1×
“Numerous studies demonstrated a good concordance between tissue and cfDNA testing of RAS mutations in patients with mCRC [11,25–28].”
ResultEl Messaoudi, S., Mouliere, F., Du Manoir, S., Bascoul-Mollevi, C., Gillet, B., Nouaille, M., Fiess, C., Crapez, E., Bibeau, F., Theillet, C., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0297 · Cited by 171 · cited 1×
“…patients diagnosed initially with wild-type mCRC. Circulating tumor DNA (ctDNA) levels are found to correlate with a number of biological and clinicopathological characteristics, including tumor burden, stage, histotype, apoptotic rate, proximity to blood vessels, and metastatic potential [19–21].”
BackgroundSchmiegel, W., Scott, R. J., Dooley, S., Lewis, W., Meldrum, C. J., Pockney, P., Draganic, B., Smith, S., Hewitt, C., Philimore, H., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12023 · Cited by 152 · cited 1×
“Similar previous studies showed a concordance of 89.7–93.3%, which indicates that the detection of RAS mutations in the blood through liquid biopsy and BEAMing technology may be a useful replacement to tumor testing [26,28,44].”
ResultInfluentialClinical utility of circulating tumor DNA for colorectal cancer
Osumi, H., Shinozaki, E., Yamaguchi, K., & Zembutsu, H. (2019) · Cancer Science · doi:10.1111/cas.13972 · Cited by 149 · cited 1×
“CRC may contain resistant mutant clones before treatment, and the proportion of these resistant clones increases under treatment [50].”
BackgroundKim, M.-J., Lee, H. S., Kim, J. H., Kim, Y. J., Kwon, J. H., Lee, J.-O., Bang, S.-M., Park, K. U., Kim, D.-W., Kang, S.-B., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-347 · Cited by 140 · cited 1×
“Numerous studies investigating inter-tumor heterogeneity (between primary tumors and metastases in the same patient) have demonstrated mutational discordance in up to 30% of cases [24,56,57].”
BackgroundThe value of cell‐free DNA for molecular pathology
Stewart, C. M., Kothari, P. D., Mouliere, F., Mair, R., Somnay, S., Benayed, R., Zehir, A., Weigelt, B., Dawson, S., Arcila, M. E., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5048 · Cited by 125 · cited 1×
“In ctDNA sequencing, the sensitivity of detecting mutant allele frequency (MAF) or variant allele frequency (VAF) is pivotal for evaluating the effectiveness of an NGS-based ctDNA profiling assay [42,43].”
MethodNormanno, N., Abate, R. E., Lambiase, M., Forgione, L., Cardone, C., Iannaccone, A., Sacco, A., Rachiglio, A. M., Martinelli, E., Rizzi, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx417 · Cited by 119
Yarom, N., & Jonker, D. J. (2011) · PubMed · Cited by 110
Mao, C., Wu, X.-Y., Yang, Z.-Y., Threapleton, D. E., Yuan, J.-Q., Yu, Y.-Y., & Tang, J.-L. (2015) · Scientific Reports · doi:10.1038/srep08065 · Cited by 107 · cited 1×
“In patients with wild-type RAS primary tumors, 10% of the metastatic lesions have RAS mutations [55].”
BackgroundSiena, S., Sartore-Bianchi, A., Garcia-Carbonero, R., Karthaus, M., Smith, D., Tabernero, J., Van Cutsem, E., Guan, X., Boedigheimer, M., Ang, A., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx504 · Cited by 97
Bando, H., Kagawa, Y., Kato, T., Akagi, K., Denda, T., Nishina, T., Komatsu, Y., Oki, E., Kudo, T., Kumamoto, H., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0457-y · Cited by 91 · cited 2×
“The concordance rate between plasma-and tissue-BEAMing was 86.4% [25].”
BackgroundResultInfluentialGarcía‐Foncillas, J., Tabernero, J. M., Élez, E., Aranda, E., Benavides, M., Camps, C., Lewintre, E. J., López‐López, R., Muinelo‐Romay, L., Montagut, C. O., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0293-5 · Cited by 89 · cited 3×
“BEAMing enables the detection of uncommon DNA sequences (e.g., those carrying a RAS mutation) with high resolution by dividing the PCR procedure into numerous individual reactions [26].”
BackgroundMethodResultInfluentialDemuth, C., Spindler, K. G., Johansen, J. S., Pallisgaard, N., Nielsen, D. L., Høgdall, E. V. S., Vittrup, B., & Sørensen, B. S. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.07.013 · Cited by 83 · cited 2×
“This study also showed that, in cases with sparse material from mCRC patients, smaller plasma volumes may often be sufficient for KRAS mutation detection by ddPCR [40].”
BackgroundMethodJing, C., Mao, X., Wang, Z., Sun, K., Ma, R., Wu, J., & Cao, H. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9210 · Cited by 68 · cited 1×
“It does not only identify point mutations, but also detects insertions, deletions, gene amplifications and microsatellite instability [41].”
BackgroundKim, T. W., Peeters, M., Thomas, A., Gibbs, P., Hool, K., Zhang, J., Ang, A. L., Bach, B. A., & Price, T. J. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3377 · Cited by 63 · cited 1×
“This phenomenon has been confirmed in several reports, although the rate of patients who become RAS-mutant at progression significantly differs among the various studies [10,15,22,30,51–54].”
ResultToledo, R. A., Cubillo, A., Vega, E., Garralda, E., Álvarez-Gallego, R., Varga, L. U. D. L., Rodríguez-Pascual, J., Sánchez, G., Sarno, F., Prieto, S. H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13311 · Cited by 63 · cited 1×
“This phenomenon has been confirmed in several reports, although the rate of patients who become RAS-mutant at progression significantly differs among the various studies [10,15,22,30,51–54].”
ResultBos, M. K., Nasserinejad, K., Jansen, M. P. H. M., Steendam, C. M. J., Angus, L., Atmodimedjo, P. N., de Jonge, E., Dinjens, W. N. M., van Schaik, R. H. N., Re, M. D., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12827 · Cited by 61 · cited 1×
“In ctDNA sequencing, the sensitivity of detecting mutant allele frequency (MAF) or variant allele frequency (VAF) is pivotal for evaluating the effectiveness of an NGS-based ctDNA profiling assay [42,43].”
MethodVitiello, P. P., Falco, V. D., Giunta, E. F., Ciardiello, D., Cardone, C., Vitale, P., Zanaletti, N., Borrelli, C., Poliero, L., Terminiello, M., et al. (2019) · Cancers · doi:10.3390/cancers11101504 · Cited by 60 · cited 4×
“…13), Exon 3 (codon 59, 61), Exon 4 (codon 117, 146); BRAF (5 mutations)—Exon 15, codon 600 (BRAF V600E, BRAF V600D, BRAF V600K, BRAF V600 R) 3 of 12 The performance of the rtPCR Idylla© Biocartis platform as a method for determining these mutations has been highlighted by numerous studies [14,18].”
BackgroundMethodInfluentialFuruki, H., Yamada, T., Takahashi, G., Iwai, T., Koizumi, M., Shinji, S., Yokoyama, Y., Takeda, K., Taniai, N., & Uchida, E. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.01.224 · Cited by 47
Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer
Patelli, G., Mauri, G., Tosi, F., Amatu, A., Bencardino, K. B., Bonazzina, E. F., Pizzutilo, E. G., Villa, F., Calvanese, G., Agostara, A. G., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0079 · Cited by 46 · cited 2×
“Besides primary resistance mechanisms, the efficacy of anti-EGFR agents in mCRC is limited by the development of molecular alterations producing acquired resistance [7,16,48,49].”
BackgroundSignificance of Liquid Biopsy for Monitoring and Therapy Decision of Colorectal Cancer
Klein‐Scory, S., Maslova, M., Pohl, M., Eilert-Micus, C., Schroers, R., Schmiegel, W., & Baraniskin, A. (2018) · Translational Oncology · doi:10.1016/j.tranon.2017.12.010 · Cited by 46 · cited 1×
“Genomic instability plays a critical role in carcinogenesis and cancer resistance to specific treatments, and leads to intra-and intertumoral heterogeneity [46].”
BackgroundMolecular pathways: sensitivity and resistance to anti-EGFR antibodies
Bertotti, A., & Sassi, F. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0848 · Cited by 45 · cited 1×
“Besides primary resistance mechanisms, the efficacy of anti-EGFR agents in mCRC is limited by the development of molecular alterations producing acquired resistance [7,16,48,49].”
BackgroundA review on the Idylla platform: towards the assessment of actionable genomic alterations in one day
Uguen, A., & Troncone, G. (2018) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205189 · Cited by 43 · cited 1×
“The Idylla system (Biocartis, Mechelen, Belgium) is a fully automated, real-time PCR-based molecular diagnostics system that can rapidly and without preanalytical DNA extraction identify oncogenic mutations, such as in the KRAS gene, in tissue and plasma samples [45].”
MethodPeeters, M., Price, T. J., Boedigheimer, M. J., Kim, T. W., Ruff, P., Gibbs, P., Thomas, A., Demonty, G., Hool, K., & Ang, A. L. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2072 · Cited by 40 · cited 1×
“High concordance between liquid biopsy and tissue biopsy for tumor molecular profiling has been previously demonstrated [23].”
BackgroundTakayama, Y., Suzuki, K., Muto, Y., Ichida, K., Fukui, T., Kakizawa, N., Ishikawa, H., Watanabe, F., Hasegawa, F., Saito, M., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25309 · Cited by 39
Mendelsohn, J., Prewett, M., Rockwell, P., & Goldstein, N. I. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2491 · Cited by 36 · cited 1×
“Cetuximab is also capable of eliciting immune functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), which serves as an anti-tumor effect [3].”
BackgroundYamada, T., Matsuda, A., Takahashi, G., Iwai, T., Takeda, K., Ueda, K., Kuriyama, S., Koizumi, M., Shinji, S., Yokoyama, Y., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01691-0 · Cited by 36
Lim, Y., Kim, S., Kang, J., Kim, H., Jang, H. S., Han, H., Kim, H., Kim, M. J., Lee, K.-H., Ryoo, S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-95345-4 · Cited by 34
Erve, I. V. ’., Greuter, M. J. E., Bolhuis, K., Vessies, D. C. L., Leal, A., Vink, G. R., van den Broek, D. A., Velculescu, V. E., Punt, C. J. A., Meijer, G. A., et al. (2020) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2020.09.002 · Cited by 33
Maurel, J., Alonso, V., Escudero, P., Fernández-Martos, C., Salud, A., Méndez, M., Gallego-Plazas, J., Rodríguez, J. R., Martín-Richard, M., Fernández-Plana, J., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00289 · Cited by 28 · cited 1×
“This phenomenon has been confirmed in several reports, although the rate of patients who become RAS-mutant at progression significantly differs among the various studies [10,15,22,30,51–54].”
ResultClonal Hematopoiesis and Liquid Biopsy in Gastrointestinal Cancers
Croitoru, V. M., Cazacu, I. M., Popescu, I., Paul, D., Dima, S., Croitoru, A. E., & Tănase, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.772166 · Cited by 24 · cited 1×
“One method to overcome this challenge could be the simultaneous genotyping of cfDNA and white blood cells DNA [60].”
MethodSelf-citationA Real-World Application of Liquid Biopsy in Metastatic Colorectal Cancer: The Poseidon Study
Procaccio, L., Bergamo, F., Daniel, F., Rasola, C., Munari, G., Biason, P., Crucitta, S., Barsotti, G., Zanella, G., Angerilli, V., et al. (2021) · Cancers · doi:10.3390/cancers13205128 · Cited by 16 · cited 1×
“This supports the use of liquid biopsy and ddPCR in routine mCRC care, especially for rapid decision-making on first-line therapy [38].”
MethodThomsen, C. B., Andersen, R. F., Lindebjerg, J., Hansen, T. F., Jensen, L. H., & Jakobsen, A. K. M. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.10.004 · Cited by 11
Rachiglio, A. M., Forgione, L., Pasquale, R., Barone, C. A., Maiello, E., Antonuzzo, L., Cassata, A., Tonini, G., Bordonaro, R., Rosati, G., et al. (2022) · Cancers · doi:10.3390/cancers14041052 · Cited by 11
Germetaki, T., Nicholls, C., Adams, R., Braun, M., Rogan, J., Moghadam, S., Lenfert, E., Lukas, A., Edelstein, D. L., Jones, F. S., et al. (2020) · Future Oncology · doi:10.2217/fon-2020-0523 · Cited by 7
Lastraioli, E., Bettiol, A., Iorio, J., Limatola, E., Checcacci, D., Parisi, E., Bianchi, C., Arcangeli, A., Iannopollo, M., Costanzo, F. D., et al. (2023) · Cells · doi:10.3390/cells12111458 · Cited by 5
Chibaudel, B. (2018) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2018.06.001409 · Cited by 3 · cited 2×
“…13), Exon 3 (codon 59, 61), Exon 4 (codon 117, 146); BRAF (5 mutations)—Exon 15, codon 600 (BRAF V600E, BRAF V600D, BRAF V600K, BRAF V600 R) 3 of 12 The performance of the rtPCR Idylla© Biocartis platform as a method for determining these mutations has been highlighted by numerous studies [14,18].”
MethodGuerrera, L. P., Napolitano, S., Falco, V. D., Giunta, E. F., Vitiello, P. P., Gravina, A. G., Suarato, G., Perrone, A., Napolitano, R., Martinelli, E., et al. (2021) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2021.07.005 · Cited by 3 · cited 1×
“Testing for these mutations is essential as they serve as predictive biomarkers for both primary and acquired resistance [5].”
Background
Cited by
Vdokaki, M.-E., Christopoulou, N.-M., Tsikas, P. K., & Christopoulos, T. K. (2025) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2025.117837 · Cited by 3
Hisamatsu, Y., Ando, K., Kudo, K., Nakanishi, R., Kawazoe, T., Zaitsu, Y., Kusumoto, T., Hata, T., Kagawa, Y., Yoshizumi, T., et al. (2025) · Cancer Science · doi:10.1111/cas.70114 · Cited by 2
“Therefore, genes such as RAS and BRAF , for which there tend to be numerous variants in subclones, may not be good choices for MRD testing [28].”
Henrykowska, G., Bartusik-Aebisher, D., Dynarowicz, K., Ramesh, T. S., Smolak, B., & Aebisher, D. (2026) · Pharmaceuticals · doi:10.3390/ph19071041 · Cited by 1
“…RAS mutations, which can be missed by conventional sequencing, can also lead to intrinsic resistance, necessitating the need for highly sensitive methods like next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) analysis to detect mutations and guide treatment strategies [14].”
Liquid Biopsies and Circulating Tumor DNA
Martínez‐Useros, J. (2026) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-032-24071-2_11
Guo, L., Song, J., Zang, H., Cao, Y., Lin, Y., Zheng, Z., Chen, S., Wen, L., Miao, Y., & Gu, W. (2026) · Hematological Oncology · doi:10.1002/hon.70218
Metadata
- Authors
- Popescu, I., Croitoru, V. M., Croitoru-Cazacu, I. M., Dudau, A.-M., Herlea, V., Dima, S. O., & Croitoru, A. E.
- Affiliations
- Faculty of Medicine, Titu Maiorescu University, 031593 Bucharest, Romania
- Titu Maiorescu University (RO)
- Department of Oncology, Fundeni Clinical Institute, 022328 Bucharest, Romania
- Carol Davila University of Medicine and Pharmacy (RO)
- Institutul Clinic Fundeni (RO)
- ORCID
- Venue
- Journal of Personalized Medicine
- Publisher
- MDPI AG
- Published
- 2024-07-15
- Volume
- 14
- Issue
- 7
- Pages
- 750
- ISSN
- 2075-4426 (ISSN-L)
- PMC
- PMC11278408
- OpenAlex
- W4400668183
- Cited by
- 4
- References
- 61
- Citations by year
- 2026: 2 · 2025: 2
- FWCI
- 0.21
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Personalized Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- RAS mutations, circulating tumor DNA, liquid biopsy, metastatic colorectal cancer, EGFR inhibitors, acquired drug resistance, intertumoral heterogeneity, clonal hematopoiesis, first-line therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
